Prosecution Insights
Last updated: November 20, 2026
Application No. 18/973,967

METHODS AND COMPOSITIONS FOR DRUGS TO TREAT OPHTHALMIC DISEASES

Non-Final OA §112
Filed
Dec 09, 2024
Priority
Aug 20, 2018 — provisional 62/719,938 +2 more
Examiner
WHITE, DAWANNA SHAR-DAY
Art Unit
1627
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Duke University
OA Round
1 (Non-Final)
63%
Grant Probability
Moderate
1-2
OA Rounds
1y 6m
Est. Remaining
84%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
82 granted / 130 resolved
+3.1% vs TC avg
Strong +21% interview lift
Without
With
+21.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
59 currently pending
Career history
203
Total Applications
across all art units

Statute-Specific Performance

§101
3.6%
-36.4% vs TC avg
§103
34.9%
-5.1% vs TC avg
§102
13.9%
-26.1% vs TC avg
§112
21.4%
-18.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 130 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . All previous objections and rejections not reiterated herein were overcome by claim amendments, filed December 9th, 2024, that have been fully considered and found persuasive. As such all objections and rejections not reiterated herein have been withdrawn. Claim Objections Claim 1 is objected to because of the following informalities: missing the word “form”. Claim 1 recites, in line 4, the limitation where “R5 and R6 together may a 3 to 7-member cycloalkyl ring”; however, claim 1 should recite,” should recite “R5 and R6 together may form a 3 to 7-member cycloalkyl ring”. Appropriate correction is required. Claim 7 is objected to because of the following informalities: missing the word “form”. Claim 7 recites, in lines 10 – 11, the limitation where “R5 and R6 together may a 3 to 7-member cycloalkyl ring”; however, claim 1 should recite,” should recite “R5 and R6 together may form a 3 to 7-member cycloalkyl ring”. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 20 – 21 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 20, the phrase "such as" in line 2 of the claim renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. See MPEP § 2173.05(d). As a consequence, one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. Specifically one of ordinary skill in the art would not be reasonably apprised of where the limitation after the “such as,” is required or not. Therefore, given the uncertainty around the limitations after the “such as,” claim 20 is rejected under 35 U.S.C. 112(b). Regarding claim 21, the phrase "such as" in line 2 of the claim renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. See MPEP § 2173.05(d). As a consequence, one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. Specifically one of ordinary skill in the art would not be reasonably apprised of where the limitation after the “such as,” is required or not. Therefore, given the uncertainty around the limitations after the “such as,” claim 21 is rejected under 35 U.S.C. 112(b). Discussion of the prior art The closest prior art of Tokumitsu et. al. ((2002), STO-609, a Specific Inhibitor of the Ca2+/Calmodulin-dependent Protein Kinase Kinase, Journal of Biological Chemistry, 18, 15813-15818) teach compound STO-609 of structure PNG media_image1.png 200 400 media_image1.png Greyscale where X = O; Y = CR5R6 where R5 and R6 come together to form a phenyl; R1 = -COOH; and R2 = R3 = H. See page 15814. However, the prior art of Tokumitsu et. al. fail to teach a compound having the Formula (XX) PNG media_image2.png 344 142 media_image2.png Greyscale where R5 and R6 are independently hydrogen (H), C1-C5 alkyl, or R5 and R6 together may a 3 to 7-member cycloalkyl ring. See claim 1 limitation. Moreover, the prior art of Tokumitsu et. al. fail to teach a compound having the Formula (XXI) PNG media_image3.png 358 176 media_image3.png Greyscale . See claim 7 limitation. Now while the prior art compound STO-609 has a ring; the ring of STO-609 is an aromatic ring which is unsaturated, that is does not have the maximum number of H atoms, and contains double bonds. Whereas the compound species of claims 1 and 7 where R5 and R6 come together to form a 3 to 7-member cycloalkyl ring is saturated ring system, containing no double bonds and having the maximum number of H atoms. Moreover, it is well understood in the chemical arts that there is differences in the chemical and physical properties between saturated and unsaturated ring systems. As a consequence of the above difference the ring system of STO-609 does not render obvious compound species of claims 1 and 7 where R5 and R6 come together to form a 3 to 7-member cycloalkyl ring. Thus the closest prior art teaching of STO-609 by Tokumitsu et. al. fails to anticipate and render obvious the compounds of claims 1- 5, 7 – 11; thus claims 1 – 5, and 7 – 11 are free of the prior art. Moreover claims 12 – 19 which direct to method comprising administering the compounds of either claim 1 or 7 are free of the prior art. Additionally, the prior art of Racioppi et. al. ((2012), Calcium/Calmodulin-dependent Protein Kinase Kinase 2: Roles in Signaling and Pathophysiology Journal of Biological Chemistry, 287, 31658-31665) teach that Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) is involved in regulating many important physiological and pathophysiological processes, including energy balance, adiposity, glucose homeostasis, hematopoiesis, inflammation, and cancer. See page 31658 Abstract. Moreover, specification, is enabled for the modulation of CaMKK2 activity in vitro and in vivo. See specification pages 31 – 34 Examples 2 – 5. Thus the methods of claims 12 – 19 are enabled. Given the teachings of Racioppi et. al. the method claims of Conclusion Claims 20 – 21 are rejected. Claims 1 – 5, and 7 – 19 are objected. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DAWANNA S WHITE whose telephone number is (703)756-4687. The examiner can normally be reached 7:00 am - 5:00 pm [EST] M - Th. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney Klinkel can be reached on 571-270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DAWANNA SHAR-DAY WHITE/Examiner, Art Unit 1627
Read full office action

Prosecution Timeline

Dec 09, 2024
Application Filed
Oct 20, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790323
CDK19-Selective Inhibitors, and Methods of Use Thereof
3y 9m to grant Granted Nov 10, 2026
Patent 12780807
NOVEL DIPHENAZINE COMPOUND, AND USE THEREOF FOR PREVENTING OR TREATING CANCER OR NEUROINFLAMMATORY DISEASES
2y 11m to grant Granted Nov 03, 2026
Patent 12758553
USE OF POZIOTINIB FOR THE TREATMENT OF CANCERS WITH NRG1 FUSIONS
4y 2m to grant Granted Oct 13, 2026
Patent 12753161
PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE
4y 0m to grant Granted Oct 06, 2026
Patent 12753163
DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1
3y 5m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
63%
Grant Probability
84%
With Interview (+21.1%)
3y 5m (~1y 6m remaining)
Median Time to Grant
Low
PTA Risk
Based on 130 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month